Hanyu Medical Completes RMB 500 Million Series D Funding to Advance Comprehensive Structural Heart Disease Platform

VCBeat (WeChat ID: vcbeat) has learned that on August 13, 2020, Hanyu Medical officially announced the completion of its Series D financing round, totaling RMB 500 million. The round was co-led by Honghui Capital, CPE, and Fujian Yingke Venture Capital Co., Ltd., with participation from Beijing Langzi Hanya Asset Management Co., Ltd., Beijing Lang Ma Feng VC LTD., Med-Fine Capital, Shanghai Orient Securities Capital Co., Ltd., TF Capital, Hehongjinghui Private Equity Management Company, and Chunfeng Venture Capital. The funds raised will be used to promote the market launch of the company’s flagship product, Valve Clamp, as well as to support the continuous research and development of new products. Bairong Capital served as the exclusive financial advisor for this financing round.

Dai Yufeng, Chairman of Hanyu Medical, stated, “We are deeply grateful for the continued recognition from numerous professional investment institutions in this round of financing. Hanyu’s core product, the transapical mitral valve repair device Valve Clamp, is the first independently developed minimally invasive interventional therapy device for mitral valve disease in China to enter pre-market clinical trials. Currently, the robust therapeutic efficacy and superior operability of Valve Clamp have received high praise and recognition from leading experts. Mitral valve disease represents the segment with the highest incidence among valvular heart diseases. We are confident in achieving rapid growth in this niche market, providing more patients with mitral valve disease with higher-quality and more effective treatment solutions. Meanwhile, we have multiple products under development, striving to build a comprehensive platform for structural heart disease products.”

Hanyu Medical, established in December 2016, is the first domestic enterprise dedicated to the research and development, manufacturing, and sales of interventional valve medical devices. The company’s core product, Valve Clamp, is a mitral valve intervention device designed for minimally invasive treatment of mitral regurgitation. Valve Clamp holds fully independent domestic patent rights and has filed international PCT patents. The product features advantages such as a simple structure, ease of operation, minimal invasiveness, and broad applicability. In October 2018, Valve Clamp completed an exploratory clinical trial involving 12 human subjects, achieving a 100% success rate and a 100% efficacy rate, with no serious complications reported, thereby attracting widespread attention from the industry and the public. As the first independently developed mitral valve minimally invasive intervention device in China to enter pre-market clinical trials, Valve Clamp is currently in the pre-market clinical stage and is poised to become the second mitral valve repair device marketed in China, following Abbott.

Honghui Capital (HLC) is an investment institution focused on the “Healthy Living” sector, dedicated to serving leading enterprises that provide technological products and differentiated services for human disease diagnosis and treatment as well as healthy living. It has in-depth research and practical experience in bioengineering, medical devices, diagnostic equipment, personal care, and healthcare. The firm manages dual-currency funds in RMB and USD, with total assets under management exceeding RMB 10 billion. Its portfolio includes high-quality investments such as Mindray Medical, Pharmaron, WuXi AppTec, WuXi Biologics, Yuwell Medical, Borui Medicine, Kintor Pharmaceutical, Genetron Health, Sansure Biotech, United Imaging Healthcare, ZENTALIS, MALO, BEABA, SMORE, and Nayuki’s Tea.

CPE, established in June 2008, is an independently operated, market-oriented asset management firm dedicated to uncovering investment opportunities in China and internationally that are aligned with the growth of China’s national economy. Adhering to a long-term investment strategy and the core philosophy of “creating value through professionalism,” the firm focuses on key sectors including healthcare and health, technology and industry, consumer and internet, software and business services, and real estate. CPE is committed to building long-term partnerships with its portfolio companies, supporting their sustainable development while simultaneously driving the overall progress of their respective industries and society at large. To date, the firm has invested in over 100 companies and, with assets under management exceeding RMB 100 billion, has become one of China’s leading asset management institutions.

Yingke Capital, established in 2010, is a mixed-ownership asset management company jointly invested by financial institutions, state-owned enterprises, and listed companies. Guided by its mission to discover the driving forces behind economic progress, the firm is committed to becoming the premier asset manager for financial institutions and a key strategic investor for industry leaders. It adheres to a focus on national strategies, specializing in investing in leading enterprises within the science and technology innovation sector. To date, the company has invested in nearly 200 industry-leading enterprises, cultivating three major industrial ecosystems: "Biopharmaceuticals," "Consumption Upgrade," and "Military-Civilian Integration (Military Aerospace)." It has become one of the investment institutions with the highest number of IPOs in China and is recognized as a top-tier firm in the first echelon of Chinese private equity investment by Zero2IPO, CVSource, and Financing China.

Beijing Langzi Hanya Asset Management Co., Ltd. (ALAN AMC) was established in 2016, with a registered capital of RMB 1.713 billion (fully paid-in). Its shareholders include the listed company Lancy Co., Ltd. (002612.SZ), Hana Bank Co., Ltd. (South Korea), Hana Financial Investment Co., Ltd., and other strategic institutional investors.

Langmafeng Venture Capital was established in September 2007, with assets under management exceeding RMB 8 billion. In 2019, it was recognized as one of the “Top 10 Investment Institutions in Advanced Manufacturing” by Lieyunwang and Investors.cn; in 2020, it received honors such as “China’s Top 50 Best Venture Capital Firms of 2019” by China Venture. As of the end of June 2020, Langmafeng Venture Capital had cumulatively invested in more than 160 companies, focusing on high-tech sectors including biopharmaceuticals and medical devices, next-generation information technology, high-end equipment, and new materials.

Med-Fine Capital is a specialized investment fund focused on the pharmaceutical, healthcare, and life sciences sectors. The fund’s management team possesses extensive industry expertise in pharmaceuticals and healthcare, along with rich experience in venture capital. It has completed investments in approximately forty emerging companies, including TianGuangShi (antibody drugs), Hanyu Medical (cardiovascular interventional devices), Zhanrong Pharma (new drug R&D), QiuZhen Medicine (tumor sequencing), LingKe Pharma (new drug R&D), AnSong Technology (orthopedic devices), JiaJian Medicine (genetic sequencing), Micron Biology (POCT), and SaiFu Pharma (CRO).

Shanghai Orient Securities Capital Co., Ltd., established in February 2010, is a wholly-owned private equity subsidiary of Orient Securities. It was ranked among the Top 10 Securities Firm Direct Investment Firms and the Top 50 Private Equity Investment Institutions by Zero2IPO in 2017, 2018, and 2019, and won the Golden Bull Award for Securities Firm Direct Investment in 2017, 2018, and 2019, placing it at the forefront of direct investment companies affiliated with Chinese securities firms.

Established in 2013, it is a venture capital firm focused on the life sciences sector, with specialization in biotechnology, new drug development, medical devices, and healthcare services.